<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Calcimedica, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock</link>
<description>Latest news and press releases for Calcimedica, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 03 Mar 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/calcimedica-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683551ce78dffbe2df0e7c6f.webp</url>
<title>Calcimedica, Inc. Common Stock</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock</link>
</image>
<item>
<title>CalciMedica Reports 2025 Financial Results and Provides Clinical Updates</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-2025-financial-results-and-provides-clinical-updates</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-2025-financial-results-and-provides-clinical-updates</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a</description>
</item>
<item>
<title>CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-discontinuation-phase-2-120000247</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-discontinuation-phase-2-120000247</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), a population characterized</description>
</item>
<item>
<title>CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-third-quarter-2025-120100179</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-third-quarter-2025-120100179</guid>
<pubDate>Wed, 12 Nov 2025 12:01:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2025 and provided clinical and corporate updates.</description>
</item>
<item>
<title>CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-publication-jci-insight-120000497</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-publication-jci-insight-120000497</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in JCI (Journal of Clinical Investigation) Insight of data from a preclinical study investigating one of its proprietary drug candidates, CM5480, as a potential new therapy for pulmonary arterial hyper</description>
</item>
<item>
<title>CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-presents-data-preclinical-study-120000370</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-presents-data-preclinical-study-120000370</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a poster presentation titled, "Store-Operated Calcium-Channel Inhibitor Auxora Improves Kidney Function Following Ischemia-Induced AKI in Rats" at the American Society of Nephrology (ASN) Kidney Week 2025. The poste</description>
</item>
<item>
<title>CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-telperian-announce-collaboration-integrate-110000421</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-telperian-announce-collaboration-integrate-110000421</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, and Telperian, a clinical trial intelligence company, today announced a collaboration on the integration of Telperian's artificial intelligence (AI) engine into the analysis of clinical trial datasets from completed clinical trials</description>
</item>
<item>
<title>CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-participate-h-c-wainwright-110000459</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-participate-h-c-wainwright-110000459</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET.</description>
</item>
<item>
<title>CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-second-quarter-2025-110000476</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-second-quarter-2025-110000476</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2025 and provided clinical and corporate updates.</description>
</item>
<item>
<title>CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-participate-h-c-wainwright-110000410</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-participate-h-c-wainwright-110000410</guid>
<pubDate>Tue, 08 Jul 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:00 p.m. ET.</description>
</item>
<item>
<title>CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-publication-american-journal-110000212</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-publication-american-journal-110000212</guid>
<pubDate>Wed, 25 Jun 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in the American Journal of Nephrology (AJN) highlighting the design and rationale of the Company's Phase 2 KOURAGE trial of lead candidate Auxora™ in acute kidney injury (AKI) with respiratory failure.</description>
</item>
<item>
<title>CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-upcoming-symposium-43rd-110000674</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-upcoming-symposium-43rd-110000674</guid>
<pubDate>Thu, 12 Jun 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy.</description>
</item>
<item>
<title>CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-first-quarter-2025-110000412</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-first-quarter-2025-110000412</guid>
<pubDate>Wed, 14 May 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended March 31, 2025 and provided clinical and corporate updates.</description>
</item>
<item>
<title>CalciMedica Announces Presentations at Upcoming Medical Meetings</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-presentations-upcoming-medical-110000162</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-presentations-upcoming-medical-110000162</guid>
<pubDate>Thu, 17 Apr 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at Digestive Disease Week (DDW) 2025 being held May 3-6 in San Diego, CA, and the participation of Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica,</description>
</item>
<item>
<title>CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-participate-jones-healthcare-technology-110000465</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-participate-jones-healthcare-technology-110000465</guid>
<pubDate>Tue, 01 Apr 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 11:00 a.m. PT.</description>
</item>
<item>
<title>CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-2024-financial-results-110000200</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-2024-financial-results-110000200</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024 and provided clinical and corporate updates.</description>
</item>
<item>
<title>CalciMedica Secures Credit Facility for Up to $32.5 Million</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-secures-credit-facility-32-120000258</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-secures-credit-facility-32-120000258</guid>
<pubDate>Wed, 05 Mar 2025 12:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $32.5 million. Proceeds from the facility are intended to support</description>
</item>
<item>
<title>CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-presents-aki-data-post-120000286</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-presents-aki-data-post-120000286</guid>
<pubDate>Tue, 04 Mar 2025 12:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, delivered a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) on M</description>
</item>
<item>
<title>CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-upcoming-plenary-presentation-120000500</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-upcoming-plenary-presentation-120000500</guid>
<pubDate>Wed, 19 Feb 2025 12:00:00 GMT</pubDate>
<description>CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San Diego, CA.</description>
</item>
<item>
<title>CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-appointment-of-dr-alan-glicklich-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-announces-appointment-of-dr-alan-glicklich-to-board-of-directors</guid>
<pubDate>Tue, 14 Jan 2025 05:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates</title>
<link>https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-third-quarter-2024-financial-results-and-provides-clinical-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/calcimedica-inc-common-stock/news/calcimedica-reports-third-quarter-2024-financial-results-and-provides-clinical-and-corporate-updates</guid>
<pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
<description>Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in</description>
</item>
</channel>
</rss>